Biotechnology stocks are losing favor as Treasury yields surge, denting the appeal of high-risk, high-reward biotech plays. The Nasdaq Biotech Index has fallen 3.8% since its Aug. 19 peak, while the 10-year yield jumped nearly half a percentage point and briefly hit 5.34%, its highest since 2002. Although the index remains up 25% this year, the pullback signals that soaring yields are spooking investors who now have safer bonds offering higher returns.
Biotech stocks, often viewed as lottery tickets with potential for massive gains or total losses, are uniquely vulnerable to rate hikes. William Soliman of White Manna Capital notes that early-stage biotechs face a tougher value proposition with better risk-free alternatives available. Nearly 75% of biotech firms have been unprofitable, and about half have less than six months of cash on hand.
In a higher rate environment, investors demand more compensation for clinical, regulatory, and financing risks. Despite the headwinds, some remain bullish: Moderna shares are up over 700% in 2026 following positive trial data, and Revolution Pharmaceuticals gained over 140% after FDA approval for advanced pancreatic cancer treatment.
Source: Bloomberg Markets · Summarized by HeadlinesBriefing